Tuberculosis (TB) is the world’s leading cause of death from a single infectious agent, affecting more than 10 million people each year and caused an | Genetics And Genomics ...
Zacks Investment Research on MSN
NTRA debuts Zenith Genomics next-gen sequencing test for rare diseases
Natera NTRA announced the commercial launch of Zenith genomics, a next-generation whole genome sequencing assay designed to ...
Market Outlook and Growth TrajectoryThe global next generation sequencing market is poised to experience robust expansion, registering an estimated growth rate of around 15% over the next five years.
The rapid evolution of HIV under antiretroviral pressure necessitates ongoing surveillance of drug resistance mutations. Next-generation sequencing (NGS) has emerged as a transformative technology in ...
Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...
Routine newborn screening (NBS) has transformed early disease detection. However, traditional biochemical tests limit the range of conditions that can be identified at birth. Next-generation ...
Twice the output, half the runtime, and half the footprint of the UG 100® with greater flexibility and improved genomic coverage Introducing two new high-throughput instrument configurations ...
PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced that Basecamp Research, a frontier AI lab for therapeutic design, has selected PacBio HiFi ...
A new ultra-high-throughput sequencing platform boosts output, speeds turnaround, and improves genome coverage. It reduces costs, broadens clinical applications, and accelerates large-scale genomics ...
Janina Krumbeck, PhD, discusses the clinical advantages of next-generation sequencing over traditional culture and how this untargeted diagnostic approach provides comprehensive pathogen ...
Dual-omic analysis to reveal gene regulatory network of immune landscape in childhood solid tumors and implications for immunotherapy. Phase 1/2 study of TSN222, a novel dual action tumor immune ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results